Insider Selling: Pediatrix Medical Group, Inc. (NYSE:MD) Director Sells 27,600 Shares of Stock

Pediatrix Medical Group, Inc. (NYSE:MD) Director Mark S. Ordan sold 27,600 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the transaction, the director now directly owns 138,683 shares in the company, valued at approximately $2,128,784.05. The trade was a 16.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Pediatrix Medical Group Price Performance

NYSE:MD traded down $0.48 during trading hours on Thursday, hitting $14.74. 609,260 shares of the stock traded hands, compared to its average volume of 867,810. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. Pediatrix Medical Group, Inc. has a 1 year low of $6.62 and a 1 year high of $16.41. The stock has a 50 day moving average price of $12.38 and a 200 day moving average price of $9.77. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -4.97, a price-to-earnings-growth ratio of 2.22 and a beta of 1.55.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm had revenue of $511.20 million during the quarter, compared to analysts’ expectations of $498.87 million. During the same quarter last year, the business posted $0.29 earnings per share. The firm’s revenue was up .9% on a year-over-year basis. Sell-side analysts forecast that Pediatrix Medical Group, Inc. will post 1.25 EPS for the current fiscal year.

Institutional Trading of Pediatrix Medical Group

Several hedge funds have recently bought and sold shares of MD. Rubric Capital Management LP lifted its stake in Pediatrix Medical Group by 797.0% in the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after purchasing an additional 7,241,400 shares in the last quarter. Dana Investment Advisors Inc. grew its holdings in shares of Pediatrix Medical Group by 80.3% in the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after purchasing an additional 455,785 shares in the last quarter. Boston Partners grew its holdings in shares of Pediatrix Medical Group by 34.0% in the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after purchasing an additional 453,254 shares in the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of Pediatrix Medical Group by 639.4% in the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock valued at $2,192,000 after purchasing an additional 251,072 shares in the last quarter. Finally, ClariVest Asset Management LLC purchased a new position in shares of Pediatrix Medical Group in the second quarter valued at $1,721,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on MD shares. Deutsche Bank Aktiengesellschaft raised their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Mizuho upped their price objective on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. UBS Group upped their price objective on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Truist Financial lifted their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Finally, Jefferies Financial Group lifted their price target on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Pediatrix Medical Group presently has a consensus rating of “Hold” and a consensus target price of $16.10.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.